Fa-Ping Wang1, Xiao-Ju Tang1, Chuan-Qi Wei1, Lin-Rui Xu1, Hui Mao1, Feng-Ming Luo2. 1. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. 2. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. Electronic address: fengmingluo@outlook.com.
Abstract
BACKGROUND: Dupilumab, a fully human monoclonal antibody against the interleukin-4-receptor α subunit, has been developed and used in clinical trials to treat atopic dermatitis (AD). OBJECTIVE: We aimed to assess the overall efficacy and safety of dupilumab treatment in AD. METHODS: PubMed, Embase, Cochrane library databases, and the Chinese Biological Medicine (CBM) published up to September 2017 were searched. All randomized controlled trials (RCTs) of dupilumab treatment on adult patients with AD were included. Fixed- or random-effects models were used to calculate pooled standard mean differences or relative risks (SMD or RR, respectively). RESULTS: Six trials involving 2447 patients were identified. Pooled analysis revealed significant improvements in Eczema Area and Severity Index (EASI) score (SMD = -0.89, 95% CI: -1.0 to -0.78), percentage of body surface area (BSA) (SMD = -0.83, 95% CI: -0.90 to -0.75), pruritus numeric rating scale (NRS) scores (SMD = -0.81, 95% CI: -0.96 to -0.66), and Dermatology Life Quality Index (DLQI) scores (SMD = -0.78, 95% CI: -0.89 to -0.66). Dupilumab treatment was also associated with a significant increase in the proportion of patients achieving Investigator's Global Assessment (IGA) response (RR = 3.82; 95% CI: 3.23 to 4.51) and a similar incidence of adverse events (RR = 1.0; 95% CI: 0.96 to 1.04). CONCLUSIONS: Our analysis provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. Dose regimens of 300 mg qw and q2 w seemed to have similar benefits. Further long-term trials are required for confirmation.
BACKGROUND:Dupilumab, a fully human monoclonal antibody against the interleukin-4-receptor α subunit, has been developed and used in clinical trials to treat atopic dermatitis (AD). OBJECTIVE: We aimed to assess the overall efficacy and safety of dupilumab treatment in AD. METHODS: PubMed, Embase, Cochrane library databases, and the Chinese Biological Medicine (CBM) published up to September 2017 were searched. All randomized controlled trials (RCTs) of dupilumab treatment on adult patients with AD were included. Fixed- or random-effects models were used to calculate pooled standard mean differences or relative risks (SMD or RR, respectively). RESULTS: Six trials involving 2447 patients were identified. Pooled analysis revealed significant improvements in Eczema Area and Severity Index (EASI) score (SMD = -0.89, 95% CI: -1.0 to -0.78), percentage of body surface area (BSA) (SMD = -0.83, 95% CI: -0.90 to -0.75), pruritus numeric rating scale (NRS) scores (SMD = -0.81, 95% CI: -0.96 to -0.66), and Dermatology Life Quality Index (DLQI) scores (SMD = -0.78, 95% CI: -0.89 to -0.66). Dupilumab treatment was also associated with a significant increase in the proportion of patients achieving Investigator's Global Assessment (IGA) response (RR = 3.82; 95% CI: 3.23 to 4.51) and a similar incidence of adverse events (RR = 1.0; 95% CI: 0.96 to 1.04). CONCLUSIONS: Our analysis provided evidence that dupilumab had an acceptable safety profile and resulted in clinically relevant improvements in signs and symptoms of AD. Dose regimens of 300 mg qw and q2 w seemed to have similar benefits. Further long-term trials are required for confirmation.
Authors: Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill Journal: Gut Date: 2022-05-23 Impact factor: 31.793
Authors: Eustachio Nettis; Luisa Brussino; Vincenzo Patella; Laura Bonzano; Aikaterini Detoraki; Elisabetta Di Leo; Maria Maddalena Sirufo; Cristiano Caruso; Fabio Lodi Rizzini; Mariaelisabetta Conte; Mona-Rita Yacoub; Massimo Triggiani; Erminia Ridolo; Luigi Macchia; Giovanni Rolla; Raffaele Brancaccio; Amato De Paulis; Giuseppe Spadaro; Danilo Di Bona; Angela Maria D'Uggento; Lia Ginaldi; Francesco Gaeta; Eleonora Nucera; Kliljeda Jaubashi; Danilo Villalta; Lorenzo Dagna; Domenico Ciotta; Francesco Pucciarini; Diego Bagnasco; Giorgio Celi; Fulvia Chieco Bianchi; Lorenzo Cosmi; Maria Teresa Costantino; Maria Angiola Crivellaro; Simona D'Alò; Pietro Del Biondo; Stefano Del Giacco; Mario Di Gioacchino; Linda Di Pietro; Elisabetta Favero; Sebastiano Gangemi; Gabriella Guarnieri; Enrico Heffler; Maria Stefania Leto Barone; Carla Lombardo; Francesca Losa; Andrea Matucci; Paola Lucia Minciullo; Paola Parronchi; Giovanni Passalacqua; Stefano Pucci; Oliviero Rossi; Lorenzo Salvati; Michele Schiappoli; Gianenrico Senna; Andrea Vianello; Alessandra Vultaggio; Yang Baoran; Cristoforo Incorvaia; Giorgio Walter Canonica Journal: Clin Mol Allergy Date: 2022-05-19
Authors: Marissa T Ayasse; Adnan Ahmed; Maria L Espinosa; Christina J Walker; Muhammad Yousaf; Jacob P Thyssen; Jonathan I Silverberg Journal: Arch Dermatol Res Date: 2020-11-22 Impact factor: 3.017
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751